Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
H1 2025 Interim Results
Watch Riad Mishlawi, CEO
Latest stories
Featured
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Press Release, Financial Results
07 August 2025
- Strategic insights into Hikma Injectables CMO: meeting partner expectations Insight, Corporate 14 August 2025 Strategic insights into Hikma Injectables CMO: meeting partner expectations
- Hikma R&D - Innovating clinical research: Meet Rand Alsaber Story, Life at Hikma 13 August 2025 Hikma R&D - Innovating clinical research: Meet Rand Alsaber
- Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half Press Release, Financial Results 07 August 2025 Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
- Hikma R&D - Innovating analytical research: Meet Raghad Saleh Story, Life at Hikma 28 July 2025 Hikma R&D - Innovating analytical research: Meet Raghad Saleh
